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Abstract
Chronic myeloid leukemia (CML) is a neoplasia characterized by proliferation of a myeloid cell lineage and chromo-
some translocation t(9;22) (q34;q11.2). As in the case of most cancers, the average telomere length in CML cells is
shorter than that in normal blood cells. However, there are currently no data available concerning specific individual
telomere length in CML. Here, we studied telomere length on each chromosome arm of CML cells. In situ hybrid-
ization with peptide nucleic acid probes was performed on CML cells in metaphase. The fluorescence intensity of
each specific telomere was converted into kilobases according to the telomere restriction fragment results for each
sample. We found differences in telomere length between short arm ends and long arm ends. We observed recur-
rent telomere length changes as well as telomere length maintenance and elongation in some individual telomeres.
We propose a possible involvement of individual telomere length changes to some chromosomal abnormalities in
CML. We suggest that individual telomere length maintenance is chromosome arm–specific associated with leuke-
mia cells.
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Introduction
Telomeres are the termini of eukaryotic chromosomes. Human telo-
meres are constituted of a tandem repeat of six base pairs (TTAGGG),
which are wrapped in a protein complex [1,2]. Telomere sequences are
lost in each round of cell replication because of the incomplete syn-
thesis of the G-rich strand and the enzymatic processing of the C-rich
strand [3,4]. The biogenesis of telomeres is regulated by a large num-
ber of proteins and an enzyme called telomerase. This enzyme is a
ribonucleoprotein, which counteracts the loss of telomere sequences
during cell division by adding telomeric repeats on the G-rich strand
[5]. Telomerase is active in germ cells, adult stem cells, activated im-
mune cells, and 90% of cancer cells [1,6]. However, it is absent or
expressed at low levels in most adult differentiated cells and resting
immune cells. McClintock [7] and Muller [8] initially pointed out
the important role played by telomeres in chromosome stability by
highlighting the chromosome end-to-end fusion process. Since these
pioneering observations, the research on telomeres has been a focal
point of aging and cancer studies. Telomere shortening and telomere
maintenance by telomerase or by alternative lengthening of telomere
(ALT) are some of the characteristic features of cancer cells [9,10].
Chronic myeloid leukemia (CML) is a myeloproliferative disease
characterized by a proliferation of myeloid cell lineage and chromo-
some translocation t(9;22) (q34;q11.2) [11], the so-called Philadelphia
(Ph) chromosome. This translocation generates a chimerical gene en-
coding the BCR-ABL oncogenic fusion protein that features constitu-
tive high-tyrosine kinase activity [12]. Without effective therapy, CML
irremediably progresses in three successive phases: chronic (CP), accel-
erated (AP), and blast crisis (BP). As is the case in all cancers, telomeres
play a central role in the progression of CML. Telomere shortening
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has been reported in each of the three phases of CML, and this short-
ening is accentuated during progression of the disease [13,14]. Telo-
mere length measurements in all the studies published to date have
been based on global evaluations relying on techniques such as telomere
restriction fragment (TRF) analysis and fluorescence in situ hybridi-
zation (FISH) using flow cytometry [13–15]. These two techniques
provide a global picture of telomere lengths at the genomic and cellular
levels by assessing their average length. The advent of telomere length
measurement by quantitative FISH (Q-FISH) [16] has allowed a better
understanding of telomere length at the chromosomal level. Besides the
t(9;22)(q34;q11.2) translocation, other chromosomal aberrations have
been reported during the progression of CML [17], and the critical
shortening of telomeres may be related to these chromosomal changes.
To the best of our knowledge, no extensive studies have been con-
ducted on individual telomere length in CML as yet.
The assessment of individual telomere length profiles in CML will
provide knowledge concerning specific individual telomere length
changes associated with CML. On the one hand, the data will yield
deeper insights regarding the relationship between individual telo-
mere length changes and chromosomal abnormalities. Conversely, they
will provide information on individual telomere length maintenance.
Materials and Methods
Samplings and Cell Cultures
Telomere length was measured in 21 CML patients at diagnosis.
One patient was in the AP phase, whereas the others were in the CP
phase. The average age of the patients was 45 years (range, 18-
83 years; Table 1). Specimens of cryopreserved blood and bone mar-
row were obtained from the Quebec Leukemia Cell Bank (Centre
de recherche, Hôpital Maisonneuve-Rosemont, Montreal, Quebec,
Canada). Five to ten million cells of each sample were cultured in a
5-ml Marrow Max medium (Invitrogen, Ontario, Canada) containing
20% fetal bovine serum for 48 hours. Phytohemagglutinin-stimulated
lymphocytes from 13 age-matched normal adults (4 males and 9 fe-
males) were used as controls. For each individual, 700 μl of blood
was cultured following the standard cytogenetic techniques. After har-
vesting, the cells (normal lymphocytes or leukemia cells) were sus-
pended in a methanol/acetic acid (3:1) fixative solution, and 10 μl
of fixed nucleus suspension was spread onto cleaned slides in a mod-
ified environmental control unit Thermotron (CDS-5, Thermotron,
Amsterdam, the Netherlands) [18], where temperature and relative
humidity remained constant at 22°C and 55%, respectively. The local
research ethic board of the Faculty of Medicine and Health Sciences
of the University of Sherbrooke approved the protocol used in the
study. Informed consent was obtained from each donor who provided
samples of blood or bone marrow used in the study.
Peptide Nucleic Acid FISH
The FISH technique was performed using peptide nucleic acid
(PNA) telomere probe FITC-(CCCTAA)3 (Applied Biosystems, Foster
City, CA). Hybridizations were carried out following the protocol pro-
vided by the manufacturer, with modifications based on our own and
others’ previous protocols [19,20]. Briefly, slides were left for 24 hours
at 37°C after spreading and then fixed in a 3.7% formaldehyde solu-
tion, followed by a proteinase K treatment. Next, the slide preparations
were denatured at 80°C for 3 minutes under a 24-mm × 30-mm cover-
slip in the presence of 10 μl of PNA telomere probe. Hybridization
was then carried out in the dark for 30 minutes at room temperature.
A posthybridization wash was done using 0.4× SSC containing 0.3%
NP-40 at 65°C for 2 minutes and 2× SSC/0.1% NP-40 for 2 minutes.
The slides were counterstained using 125 ng/ml 4,6-diamidino-2-
phenylindole (DAPI) mixed with 1 mg/ml p-phenylenediamine (Sigma
Aldrich, St Louis, MO). The slides were kept in the dark for 2 days at
room temperature to enhance banding patterns on chromosomes.
Table 1. Clinical Data of CML Cases.
Information at Time of Sampling No. of Metaphases
Analyzed (Q-FISH)
Samples Age Sex Tissues Blasts Karyotype Clinical Phases
02-H055 45 M Blood 5%/Blood 46,XY,t(9;22)(q34;q11.2)23 CP 10
02-H058 26 F Bone marrow 2%/BM 46,XX,t(9;22)(q34;q11.2)21 CP 11
02-H077 45 M Blood 3%/Blood 46,XY,t(9;22)(q34;q11.2)20 CP 15
03-H034 45 M Bone marrow 1%/BM 46,XY,t(9;22)(q34;q11.2)19/46,idem,?
der(7)del(7)(q11.2q21)del(7)(q36)2
CP 10
03-H044 64 F Blood 5%/Blood 46,XX,t(9;22)(q34;q11.2)21 CP 15
03-H056 18 M Blood 3%/Blood 46,XY,t(9;22)(q34;q11.2)21 CP 13
03-H061 44 F Bone marrow 10%/BM 46,XX,t(9;22)(q34;q11.2)23 AP 15
03-H077 35 F Bone marrow 5%/BM 46,XX,t(9;22)(q34;q11.2)29 CP 9
03-H079 50 F Bone marrow 2%/BM 46,XX,t(9;22)(q34;q11.2)20 CP 11
04-H013 52 M Bone marrow 5%/BM 46,XY,t(9;22)(q34;q11.2)22 CP 5
04-H015 38 F Bone marrow 3%/BM 46,XX,t(9;22)(q34;q11.2)21 CP 11
04-H035 61 F Bone marrow 2%/BM 46,XX,t(9;22)(q34;q11.2)20 CP 8
04-H057 44 M Blood 3%/Blood 46,XY,t(9;22)(q34;q11.2)20 CP 9
04-H131 33 F Bone marrow 4%/BM 46,XX,t(9;22;13)(q34;q11.2;p13)20 CP 8
05-H020 57 F Bone marrow 3%/BM 46,XX,t(9;22)(q34;q11.2)20 CP 9
05-H043 45 F Bone marrow 2%/BM 46,XX,t(9;22)(q34;q11.2)20 CP 10
05-H049 83 F Bone marrow 2%/BM 46,XX,t(9;22)(q34;q11.2)18 CP 9
05-H166 40 M Bone marrow 2%/BM 46,XY,t(9;22)(q34;q11.2)20 CP 10
06-H047 39 F Bone marrow 5%/BM 46,XX,t(9;22)(q34;q11)22 CP 7
06-H069 53 M Bone marrow 2%/BM 46,XY,t(9;22)(q34.1;q11.2)20 CP 8
06-H097 32 F Blood 7%/Blood 46,XX,t(9;22)(q34;q11.2)20 CP 9
Samplings were done at diagnosis and before the initiation of treatment. The translocation t(9;22) was the most frequent cytogenetic abnormality. More than 80% of the patients were at the CP, and 13
of 21 patients were females.
AP indicates accelerated phase; CP, chronic phase.
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Imaging and Fluorescence Measurement
The slides were examined under an Olympus BX61 microscope
(Olympus America Inc., Center Valley, PA) equipped with appropri-
ate filters. For each sample, a number of metaphases were digitally
captured using a Compulog IMAC-CCD S30 videocamera module
(MetaSystems Group Inc., Waltham, MA). Standard DAPI and fluo-
rescein isothiocyanate filters were used to display chromosome and
telomere-specific signals, respectively. Approximately 5 to 15 meta-
phases were karyotyped (Table 1) based on the quality of DAPI-banding
pattern. To determine a minimum number of metaphases to be ana-
lyzed, a widely used standard [21] was followed. According to this stan-
dard, whereas at least 50% of cells carrying the same chromosome
anomaly (very long or short telomeres at the same chromosome ends
in this study), the minimum number of five cells needs to be analyzed
on a 95% confidence limit (power) and under a 99% analytical sen-
sitivity of a specific technique such as FISH [19]. Telomere measure-
ments were done using an in situ imaging system software (ISIS 2;
MetaSystems). Fluorescein isothiocyanate fluorescence intensity was
measured on both the short-arm (p-end) and the long-arm (q-end) of
each 1 of the 46 chromosomes per cell. Therefore, each metaphase
presented 92 telomere length measurements. The length of a specific
individual telomere for a given specimen was the average of these in-
dividual telomere lengths in different metaphases.
TRF Technique
DNA was extracted from six normal individuals and from all leuke-
mia donors using the standard method of phenol-chloroform. The TRF
technique was performed using the TeloTAGGG Telomere Length
Assay kit (Roche Applied Science, Laval, Quebec, Canada). Briefly,
1.5 μg of DNA was digested using HinfI and RasI restriction enzymes.
The digested DNA was electrophoretically resolved on 0.7% Agarose
gel, transferred to a nylon membrane, and blotted with digoxigenin-
labeled (CCCTAA)3 DNA probe. The membrane was exposed to a
phosphorimager screen and detected on the PhosphorImager Storm
860 (Molecular Dynamics, Sunnyvale, CA) and then on an x-ray film.
Telomere size was measured using the Image J freeware (National Insti-
tutes of Health, Bethesda, MD).
Determination of Physical Length of Individual Telomeres
We converted individual telomere signal intensities obtained from
Q-FISH to physical length in kilobases using TRF results from CML
and normal cells, as described in previous reports [20,22], with some
modifications. Briefly, the average fluorescence intensity of meta-
phases of a given case was equated to the average length in kilobases
of TRF measurements from the same case. Next, the equivalent of a
fluorescence unit of each individual telomere was converted into kilo-
bases. The normal individual telomere lengths from peripheral blood
cells were adjusted to reflect those of hematopoietic stem cells, ac-
cording to Sakoff et al. [23].
Statistical Analysis
Descriptive statistics, including means, SDs, and confidence inter-
vals, were generated by the “proc means” and the “proc univariate”
procedures of the Statistical Analysis System (SAS) software, version
9.1.3 (SAS Institute, Inc, Cary, NC). Analysis of variance was per-
formed using four fix effects: group, with 2 levels (normal and leuke-
mia); chromosome, with 24 levels (autosomes and sex chromosomes);
chromosome arm, with 2 levels (p-end and q-end); and sexes, with
2 levels (female and male). Subjects (individual cases) served as a ran-
dom effect. The dependent variable was the physical telomere length
in kilobases. We also used the PDIFF function for the pairwise com-
parisons of the least square means, which provides a defensible esti-
mate of interesting effects. Tukey and Dunnet adjustments were
used to keep the experiment-wise rate of type I error to 5%. The in-
dividual telomere length for each CML sample was compared with its
counterpart in normal samples used as reference. Individual telomere
lengths for CML samples were defined as elongated or shortened when
their lengths were significantly longer or shorter (P < .05) than their
counterparts in the normal reference. Otherwise, they were defined as
maintained when no statistical difference (P > .05) was observed be-
tween CML cases and normal reference cases. We used orthogonal
contrasts to compare each individual telomere length of a given case
to its average telomere length. The validity of these models was con-
firmed by a normal distribution of all residuals. The statistical sig-
nificance was established for all comparisons for P < .05 at a 95%
confidence interval. The descriptive graphics were produced with the
Statistical Package for Social Sciences (SPSS) software, version 17.0
(SPSS, Inc, Chicago, IL).
Results
Longer Mean Telomere Lengths on p-Ends Rather Than on
q-Ends in CML
First, we found that telomeres on both p- and q-ends in the leu-
kemia group were significantly shorter than their counterparts in the
normal group (P < .001 for both arms; Table 2). Second, we ob-
served that in the CML group, the mean individual telomere length
for females (7.12 ± 0.11 kb) was significantly longer (P < .001) than
that for males (5.85 ± 0.121 kb), whereas the normal adult group did
not display such a difference (P = .43; Figure W1). Interestingly, we
further found that, in the leukemia group, the mean telomere length
for the p-ends (6.91 ± 0.12 kb) was statistically longer (P < .001)
than the mean for the q-ends (6.33 ± 0.10 kb), whereas the mean
telomere lengths for the two chromosome ends in the normal group
did not differ (P = .41; Table 2). In summary, we observed significant
differences in telomere length between p-ends and q-ends as well as
between females and males in the CML group.
Nonrandom Individual Telomere Length Changes in CML
We observed that the mean individual telomere lengths for each
specific chromosome ends from all cases ranged from 1.70 to
24.83 kb (Figure 1) in the CML group. Because assessing the indi-
vidual telomere lengths of all the CML cases collectively could hide
important information regarding the telomere length profile of each
case, we determined the specific individual telomere length profile for
each single case. To establish the specific individual telomere profile,
Table 2. Representation of Average Telomere Length in CML and Normal Groups.
CML Group SD SE Normal Group SD SE P
p 6.91 2.83 0.12 8.46 1.48 0.136 <.001
q 6.33 2.37 0.10 8.53 1.00 0.092 <.001
P <.001 .41
Average telomere length of all telomeres, on p-arms or q-arms of CML cells, was statistically shorter
and widely distributed than their corresponding entities in normal cells (P < .001). The values are
expressed in kilobases. The statistical method used is described in the Materials and Methods section.
p indicates chromosome short arms; q, chromosome long arms.
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we determined the longest and the shortest telomeres in relative
length for each case by comparing the mean of each specific individ-
ual telomere length to the mean of all telomeres in the sample using
orthogonal contrasts. When the mean length for a given individual
telomere was significantly greater or less than the telomere length for
that case (P < .05), it was considered to be among the longest or the
shortest telomeres, respectively. It was found that in the CML samples,
the p-ends harbored the longest telomeres, whereas the shortest telo-
meres were mainly found on the q-ends. In CML cases, the telomeres
on 18p and Xp were among the longest in 57.14% and 42.85% of
cases, respectively, whereas the telomeres on 21p and 21q were among
the shortest in 28.57% and 23.80% of cases, respectively (Figure 2).
In normal adult samples, the telomeres on 5p, 3p, and 4p were among
the longest individual telomeres in 57.14%, 42.4%, and 38.46% of
cases, respectively (Figure W2A). In contrast, the telomeres on 19p,
17p, and 20q were among the shortest in 46.15%, 38.46%, and
38.46% of cases, respectively (Figure W2B). In conclusion, specific
telomere length changes of the longest individual telomeres on 18p
and Xp, and the shortest individual telomeres on 21p and 21q seemed
to be a characteristic of CML in the CP phase.
Individual Telomere Shortening Rate in CML
To evaluate the possible evolution of specific individual telomere
lengths during leukemogenesis (initiation of CML until diagnosis), we
assessed individual telomere length shortening rates in the CML group
by measuring the relative difference [(A − B / A) × 100] in length be-
tween each specific individual telomere (A) in the normal group and
its corresponding individual telomere (B) in the CML group. We
Figure 1. Box plot of individual telomere lengths (kb) in the CML group. Black boxes correspond to chromosome short arms; shaded
boxes, chromosome long arms. The individual telomere length was shown by the mean of the specific telomere lengths in 10 meta-
phases. The dots represent the extreme value of an individual telomere length in each case. The red arrows indicate the minimum and
maximum individual telomere lengths on Xp (24.83 kb) and 12p (1.70 kb), respectively.
Figure 2. Percentage of cases showing relative individual telomere lengths among the longest (yellow bars) and the shortest (red bars) in
the CML group. In each sample, a specific individual telomere length was compared with the mean of all telomeres. When an individual
telomere was shorter or longer than the mean telomere of a case (P< .05), it was considered among the shortest or longest telomere of
that case. Chromosome numbers are shown on the x-axis. Frequently observed longest telomeres are at 18p and Xp, which were seen
in 54.14% and 42.85% of cases, respectively, whereas the shortest, at 20q, 21p, and 21q, were seen in 28.57%, 28.57%, and 23.80% of
cases, respectively.
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found that individual telomeres on the q-ends had a higher shorten-
ing rate (26.38%) than those on the p-ends (17.97%; P < .001).
Moreover, individual telomere losses were more uniform on the q-ends
(0.31%) than on the p-ends (0.88%) as variances (P = .007). Next, the
study of individual telomere shortening rates showed that telomeres
on Yp, Yq, 1q, 5q, 9q, 8p, and 21p had the highest telomere attrition
rates, and their lengths were at least 30% shorter than their counter-
parts in the normal group (Figure 3, A and B). In summary, the indi-
vidual telomere lengths on both ends of the Y chromosome presented
the highest telomere shortening rate (p-end = 34.02%, q-end =
44.52%) in the CML group.
Maintenance of Some Individual Telomere Lengths in CML
We investigated whether there were differences for specific individ-
ual telomeres between the leukemia and the normal groups by com-
paring the mean of each individual telomere length in the leukemia
group with its counterpart in the normal group. Using the PDIFF
function for pairwise comparisons of the least square means, we
found that telomeres on 11p, 14p, 17p, 18p, 19p, and Xp were
maintained in the CML group because data showed no statistical dif-
ference (P > .05) in mean telomere lengths between the CML and
the normal groups for these particular telomeres (Figure 3A). In con-
trast, all individual telomeres on the q-ends in the normal group were
statistically longer than the corresponding individual telomeres in the
leukemia group (P < .05; Figure 3B).
Presence of Some Long Telomeres in CML in the CP Phase
To evaluate the elongation of each specific individual telomere in
CML cases, we compared the mean length for each specific individ-
ual telomere in each CML case to its counterpart mean in the normal
group. We used the PDIFF function and Dunnet adjustment for
multiple comparisons. This approach helped to eliminate the group
effect and to show the elongation or shortening of a specific individ-
ual telomere in each sample in reference to the normal. We noticed
telomere elongation events on some chromosome arms, such as 14p
and 18p, in 14.3% of CML cases (Figure 4A). Interestingly, in all
CML cases, telomere sequences on 19p were maintained or elongated
because no shortening was observed for this chromosome end. In addi-
tion, individual telomeres on 5p, 9p, 11p, 12p, 14p, 16p, 17p, 18p, 20p,
Xp, 14q, and Xq were elongated or maintained in 80% of the CML
cases (Figure 4, A and B). Furthermore, we found three CML cases
that presented very long individual telomeres on Xp (24.83 kb), 3p
(18.66 kb), and 18p (16.23 kb), respectively (Figure 5, A–D). These
results were confirmed by the TRF technique, which showed specific
bands distinct from the telomere smear (Figure 6). We concluded that
some CML cells harbor specific individual long telomeres (16-25 kb)
despite average telomere shortening of the remaining telomeres.
Discussion
Progressive telomere shortening is well described in hematological
malignancies, especially at the time of diagnosis and disease relapse
[24–27]. However, little is known regarding telomere length changes
associated with specific chromosome ends in tumor cells. Owing to
the uneven distribution of telomere length on individual chromo-
some arms, studies on specific telomere changes could have impact
on chromosome-specific factors in relation with chromosome stability
in tumor cells. Here, we report a study of individual telomere lengths
in CML patients at diagnosis before treatment. To our knowledge, this
Figure 3.Means of individual telomere lengths on chromosome arms in normal and CML groups. The gray columns represent the mean
of individual telomere lengths in normal adults, whereas the hatched columns correspond to the mean of individual telomere lengths in
CML cases. (A) Means of individual telomere lengths on the chromosome short arms. (B) Means of individual telomere lengths on the
chromosome long arms. Error bars, 95% confidence interval.
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is the first extensive study to determine specific individual telomere
lengths in CML.
General Comparison of Telomere Lengths between CML and
Normal Cells
We showed that the average telomere length for CML patients was
shorter than for normal controls, in agreement with other reports
[13,15]. This finding was valid for telomere lengths on both chromo-
some ends because the mean telomere lengths on p- and q-ends in
CML were statistically shorter than their counterparts in normal
samples. Interestingly, we found that the average telomere length
on p-ends was significantly longer than on q-ends in CML samples.
This phenomenon can be attributed to disparate telomere erosion
rates on p- and q-ends in CML, which telomeres on q-ends had
higher and more uniform erosion rates than those on p-ends. In con-
trast, telomere lengths in normal individuals did not show the differ-
ence between p- and q-ends. Similar to previous reports from other
groups, the study on individual telomere length in vivo and in vitro
during normal aging did not show differences between p- and q-ends
in telomere lengths and in telomere shortening dynamic or telomere
erosion rate [22,28]. In addition, we found that the telomeres of fe-
male patients were significantly longer than those of male patients.
These observations pointed to the differences between CML and
normal cells with regard to telomere shortening on chromosome arms.
These differences lead to the heterogeneity of individual telomere
length profiles in CML cases and may confer a proliferative advantage
for the malignant cells.
Shortest and Longest Individual Telomeres
Tumor cells pass through many more replicative cycles than normal
cells. Consequently, telomere shortening becomes a common finding
for many types of tumors. However, little is known whether the shortest
and the longest telomeres are associated with specific chromosomes in
malignant disorders. Such a finding could imply chromosome-specific
factors involved in telomere length regulation. Our approach allowed
us to determine the shortest and longest telomeres associated with spe-
cific chromosome ends. We found that telomeres on 19p, 17p, and
20q had higher percentages of being among the shortest in normal sam-
ples, in agreement with the findings of other groups [16,22]. However,
Figure 4. Percentages of short, maintained, and long individual telomeres in CML samples. The average of each specific individual
telomere length in each CML case was compared with its corresponding individual telomere length in normal control group. Short
or long individual telomeres in each leukemia sample were defined when their respective lengths were statistically (P < .05) shorter
(black columns) or longer (white columns) than the corresponding individual telomere length in normal control. If there was no statistical
difference, they were considered as maintained (gray columns). (A) Individual telomere on the chromosome short arm. The individual
telomere on 19p was not shortened in any CML sample. (B) Individual telomere on the chromosome long arms. The 5q was shortened in
almost two-thirds of CML cases.
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telomeres on 20q, 21p, 21q, and 9q in the CML group had the
highest proportion of being among the shortest telomeres. Similarly
to the shortest telomeres, we noticed a swift in the profile of the
longest telomeres in normal and CML samples. The telomeres on
18p, Xp, 1p, and 14p were more represented among the longest telo-
meres in CML samples, whereas those on 5p, 3p, 4q, and 1p had
the highest frequencies of being the longest telomeres in normal sam-
ples. In summary, telomeres on 5p, 14p, 17p, 19p, Xp, 21p, 4q, and
9q were more prone to change their profile during leukemogenesis.
It is worth noting that, although individual telomere lengths shorten
in normal cells during aging and are different in different tissues, they
maintain the same profile under these two conditions [22,28,29].
However, individual telomere length profiles in cancer cells are dif-
ferent from those of normal cells even if they derive from the same
stem cells. Zheng et al. [30] have shown a different profile of 9p telo-
mere length in lymphocytes from normal women and breast cancer
patients, and they have suggested that this finding may be a risk
factor in breast cancer. The maintenance of telomere length as well
as the rate of shortening may have an influence on the profile change
of individual telomere in CML. In clinical settings, this change in
profile could be used as a marker to monitor the progression of the
disease and the success of the treatment. It would be of great interest
to investigate the profile changes of the individual telomeres as the
disease progresses through the AP and BP and to understand the bio-
logical meaning of these changes. Moreover, the findings could foster
research on individual telomere length in other malignancies that lack
reliable biomarkers.
Individual Telomere Shortening in CML
The terms of the “telomere shortening” and the “short telomere”
should be differentiated because the former is a dynamic process
(telomere sequence losses), whereas the latter is correlated with telo-
mere length profile. Our study on individual telomere shortening in
CML samples showed that telomeres on Yp, Yq, and 5q shortened
Figure 5. Individual telomere lengths in CML cases. Some CML cases showing individual long telomeres. Black bars represent the
p-ends, whereas gray bars represent the q-ends. (A) Representative metaphase of a CML case (02H077) showing very bright fluores-
cence on chromosome X. (B) Same case (02H077) representing the value of individual telomere in kilobases. The telomeres on Xp
measured 24.83 kb, and the average telomere of the case was 6.60 kb. (C) Case 06H069 showing elongation of telomere on 3p
(18.66 kb). Its average telomere length was 8.43 kb. (D) Case 06H097 displayed homogenous with long telomere lengths. Its average
telomere length was 12.75 kb, and the longest telomere was on 18p (16.27 kb).
Figure 6. TRF results from three normal individuals (A) and 16 CML
cases (B and C). General shortened telomeres can be seen in all
samples except for one case (lane 14, case 06H097). Some CML
show uncommon telomere fragments, which appear as fuzzy
bands (blue arrows in panel B) and represent long telomeres.
Twocases, 06H069 (lane 15) and 02H077 (lane 16), the long telomere
fragments seem as typical sharp bands (red arrows in panel C)
distinct from those short telomere fragments that are distributed
as smears in the gel. The molecular markers (kb) are labeled at left
and right sides of the panels. Their individual telomere lengths are
also shown in Figure 5.
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more rapidly than the others. Similarly, Rashid-Kolvear et al. [31]
have observed in breast cancer cells that telomeres on 17q shortened
more rapidly than the average telomere. It is tempting to suggest that
the differential shortening of individual telomeres may be a property
inherent to cancer cells.
The continuous and rapid losses of telomere sequences on both
arms of Y chromosome and on the long arm of chromosome 5 may
account for their losses in CML in late phases. These observations have
been reported as ones of the recurrent chromosomal abnormalities
observable during the progression of CML [32,33]. Besides the possi-
ble involvement of short individual telomeres in chromosomal abnor-
malities, they may also account for an estimation of the rate of cell
proliferation. Recently, Keler et al. have estimated, based on the 1-kb
difference of average telomere length between normal and CML at
the CP, that the malignant cells may undergo approximately 10 times
more cell divisions than normal cells [34]. However, this suggestion
may be an underestimation. For instance, we found that Yp and Yq
had the highest telomere sequence losses of 3.70 and 3.60 kb, re-
spectively. We can thus estimate that the number of cell divisions of
CML cells may be 30 times more than those of normal cells’. This
accelerated telomere shortening on some individual telomeres could
also be explained by an increase in enzymatic processing of specific telo-
meres due to DNA damage, which has been reported on short telo-
meres [35], or the disruption of telomere sheltering. Other studies
will be needed to elucidate mechanisms involved in the accelerated
shortening of some individual telomeres in CML and to establish their
occurrence in other malignancies.
Individual Telomere Maintenance or Lengthening
Long telomeres could have very different effects for the mainte-
nance of chromosome stability in comparison with short telomeres.
It could be therefore suggested that long telomeres located at some
specific chromosome ends may play a role to protect some “key” chro-
mosomes during cell proliferation in tumor progression. In the present
study, we found that some specific telomeres on 11p, 14p, 17p, 18p,
19p, and Xp were maintained in the CML group, and this mainte-
nance was consistent in individual CML cases. Despite their average
telomere shortening, more than 80% of these cases showed telomere
length maintenance or lengthening on these chromosomes arms. In
this connection, Krejci et al. [36] have reported a single individual
telomere lengthening on 11q and estimated its length of more than
20 kb, whereas the average telomere length was short in one case of
acute lymphoblastic B-cell leukemia. Moreover, the presence of in-
dividual telomere lengthening has been observed in some cancer cell
lines, especially in those using ALTmechanism to maintain their telo-
meres [37]. Similar to telomere shortening, individual telomere length
maintenance or lengthening may be involved in some chromosomal
abnormalities seen in CML. For instance, trisomy 19 is a recurrent
chromosomal abnormality in CML, appearing during progression of
the disease [38]. Although in our normal samples, the individual telo-
mere on 19p was among the shortest telomeres, it was maintained or
elongated in all of our CML cases. One explanation for this mainte-
nance may be the need for cells to keep chromosome 19 intact to fulfill
their neoplastic fate and even to reinforce their malignancy commit-
ment by adding one additional copy of chromosome 19. One key ele-
ment contributing to the occurrence of trisomy 19 in CML late phases
may be the maintenance of telomere length on chromosome 19p.
The lengthening of different individual telomeres in CML at the
CP could correlate with different mechanisms on the maintenance of
chromosome stability. First, the presence of some important genes on
some chromosome arms may trigger some mechanisms preserving
the integrity of these chromosomes arms by protecting telomeres’
lengths. For instance, 17p harbors some important genes, such as
p53, which has been implicated in the pathogenesis of more than
50% of cancer cases and 10% to 12% of leukemia cases [39], espe-
cially in the progression of CML from the CP to the AP [40–42].
Thus, maintenance of the telomere length may protect the chromo-
somes bearing the important genes in CML cells. Second, the pos-
sible preferential action of telomere length maintenance mechanisms
on short telomeres could ensure cell survival [43,44]. As a result,
telomerase and other telomere maintenance mechanisms may prefer-
entially act on these telomeres to maintain their length. Finally, the
cis-acting regulation of an individual telomere length may involve its
chromosome arm. Telomere recombination has been implicated in
telomere maintenance [44,45], and there is a large body of evidence
suggesting a relationship between telomere recombination and epige-
netic changes in subtelomeric DNA and chromatin [46,47]. Thus, we
can speculate that each individual chromosome arm may have specific
epigenetic features in its subtelomere region, enabling it to have con-
trol over individual telomere length regulation in CML at the CP.
In addition to normal or low telomerase activity in more than
90% of CML samples at the CP [15], the differential telomere short-
ening, the maintenance and lengthening of individual telomere, as
well as the presence of short and long telomeres as presented in this
study are suggestive of the presence of ALTmechanism to maintain
telomere length in CML cells at the CP. Further work is obviously
required to decipher the involvement of ALT in the maintenance of
individual telomere length during the different phases of CML.
Conclusions
This study sheds light on the involvement of individual telomere
changes in length in CML at diagnosis. We have defined the individ-
ual telomere length profiles and shown nonrandom individual telo-
mere length changes. We have suggested the possible involvement of
telomere length changes in CML chromosome abnormalities. Besides
a defined role of telomerase in these changes, we have suggested the
presence of an ALTmechanism that would maintain telomere length
in some individual telomeres in CML at the CP.
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Figure W1. Comparisonbetween female andmale telomere lengths.
Theaverage individual telomere length of female andmale individuals
measured was in the CML and normal groups. No statistical differ-
ence (P > .05) in telomere size existed between female (8.51 kb,
SD= 1.34 kb) and male (8.49 kb, SD= 1.22 kb) individuals in normal
group. In contrast, in the CMLgroup, females (7.12 kb, SD= 2.66 kb)
had statistical longer telomeres than males (5.85 kb, SD = 2.33 kb)
(P< .05). Gray and hatched boxes correspond to female and male in-
dividuals, respectively. Error bars are the confidence interval at 95%.
Figure W2. Representation of relative longest and shortest individual telomeres in specimens from normal individuals. In each sample, a
specific individual telomere length was compared with the mean of all telomeres. When an individual telomere was statistically (P < .05)
shorter or longer than the mean telomere of a given case, it was considered among the shortest or longest telomere of that case. (A)
Percentage of cases harboring the longest individual telomeres. The 5p, 3p, 4q, and 1p were the individual telomere having the highest
representation in this category. Xp and 18p had low representation, whereas they had frequencies of being among the longest individual
telomere in the CML group. (B) Frequencies of shortest telomere. 19p, 17p, 20q, and 16 p had the highest frequencies of being among
the shortest telomere. 21p and 21q had low frequencies of being among the shortest individual, whereas they had high representation
among the shortest individual telomere in CML samples.
